Differentiated strategies for nanovaccines in lymphoma immunotherapy: Advances and challenges

Abstract

Lymphomas constitute a molecularly and clinically heterogeneous group of hematological malignancies, classically stratified into two distinct entities: Hodgkin Lymphoma (HL) and Non-Hodgkin Lymphoma (NHL). These subtypes demonstrate fundamental divergences in their pathobiology and immune microenvironmental profiles. Nanovaccines—nanoparticle-based platforms encapsulating tumor-associated antigens (TAAs) or neoantigens—offer precision immunotherapy by enabling controlled antigen delivery and enhanced dendritic cell cross-presentation. Subtype-specific designs target EBV-associated HL (using LMP1/2 or EBNA1) or NHL (via CD19/CD20/CD22 or T-cell epitopes). However, challenges persist in the development of nanovaccines, particularly concerning antigen selection, carrier materials, and the optimization of vaccine formulations. These vaccines must overcome the immunosuppressive tumor microenvironment, ensure efficient delivery to tumor sites, and avoid toxicity. Despite these hurdles, evolving research in the immunotherapy field of lymphoma leads to the continued exploration of nanovaccines as promising additions to existing therapeutic regimens. This review serves to highlight the critical nature of further research to achieve a better understanding of the complicated interdependent interactions between nanovaccines, immune responses and tumour biology, culminating in more effective and personalised therapies for victims of lymphomas. This advanced strategy is expected to overcome the shortcomings of classic therapies including Chemo and Radiotherapy, in terms of improved specificity, fewer systemic side-effects and the potential for prolonged remission in patients with refractory or relapsed lymphomas. In conclusion, the integration of nanotechnology into lymphoma immunotherapy marks a vast advancement in the area of cancer therapy, with nanovaccines poised to play a crucial role in future therapeutic strategies.